Price-driven growth masks the real problem: volume and margins are deteriorating
Revenue surged 21.2% year-on-year, but all of it came from price inflation. The underlying business — volumes down 8.3%, EBITDA growth a bare 2.4% — signals operating leverage is now working in reverse. Guidance targets have been backed off.
₹1,304 Cr
+21.2% YoY, but volume -8.3%
₹91 Cr
+2.4% YoY only; massive deceleration vs revenue
₹52 Cr
+9.8% YoY; NPM 4.0%
₹9.79
+13% QoQ but entirely price-driven
On the surface, Filatex delivered strong growth: revenue up 21.2% year-on-year. But the numbers tell a different story. All of that growth came from price inflation; volumes actually fell 8.3%. More damaging: EBITDA grew just 2.4% year-on-year despite the 21.2% revenue jump. That 18-percentage-point gap between revenue growth and EBITDA growth signals that costs are rising faster than the company can recover them through price. The margin squeeze is real.
Where price inflation masks the real problem
Filatex sold 92,998 MT in Q2 FY27, down from 101,390 MT in Q2 FY26 — an 8.3% volume decline. The company offset this by raising prices; average realization per kg rose 21% year-on-year (₹13.98/kg vs ₹11.56/kg). That price inflation alone drove the ₹1,304 Cr revenue number. But on the EBITDA line, the picture darkens: rising raw material costs (polyester, MEG, PTA), logistics inflation, and foreign-exchange pressure have compressed margins. EBITDA per kg did improve 13% quarter-on-quarter (₹9.79 vs ₹8.67), but that gain is entirely attributable to the higher price realization, not to operational efficiency or volume leverage. When absolute volume is declining and profit-per-unit gains come only from price, the company has limited pricing power and faces structural demand weakness.
Revenue growth alone does not give a clear picture of performance, particularly when higher selling prices drive much of the increase. Absolute EBITDA is a better indicator.
Claims on the call: what held up
Sharp sequential improvement in financial performance
Revenue +13.9% QoQ to ₹1,304 Cr; but EBITDA +2.4% YoY only
Overstated
Volume increased by 3.5% QoQ to 92,998 MT
92,998 MT vs 89,872 MT in Q1 FY27 confirmed; but YoY down 8.3%
Supported
EBITDA per kg improved 13% to ₹9.79
₹9.79 vs ₹8.67 in Q1 = 12.9% improvement; accurate but driven entirely by price
Supported (caveat)
Ecosis 27K MT capacity will deliver ₹80–90 Cr EBITDA with 30%+ margins
Now 'EBITDA-positive' in Q4 FY27 at 40–50% utilization only; magnitude no longer disclosed
Contradicted
PFI expansion will add ₹150–200 Cr revenue in FY27
Now 'likely from early 2027', implying FY28 realization
Overstated
What changed from the prior quarter
On the Q1 call, management had been bullish. Ecosis (the textile-to-textile recycling plant) would deliver ₹80–90 Cr of EBITDA with 30%+ margins. The PFI expansion would contribute ₹150–200 Cr of revenue in FY27. On this quarter's call, both targets have been backed off. Ecosis is now described as 'EBITDA-positive' in Q4 FY27, running at just 40–50% capacity utilization; the ₹80–90 Cr magnitude is no longer mentioned. PFI revenue is now 'likely from early 2027'—a six-month deferral to FY28. The core business, meanwhile, is under new pressure: volumes down 8.3% YoY despite price inflation, and EBITDA growth decoupled from revenue growth. The ₹235 Cr Brownfield expansion (55K TPD) is tracking on schedule (67% commissioned, balance by late November), but the near-term earnings narrative has shifted from growth acceleration to margin defense.
The bull case and the bear case
Long-term capex (₹690 Cr Brownfield + Ecosis + 2 new plants for 2029) is credible and quantified
India-EU/UK/NZ FTA tariff cuts (+10–12% duty benefit) now live; structural tailwind for textile exporters
Domestic PTA supply (Indian Oil, GAIL) going live in FY28; reduces import volatility and cost pressure
Early-mover advantage in Ecosis with global brands (Decathlon, A&E, H&M, IKEA); proprietary glycolysis tech
Volume declining 8.3% YoY despite 21.2% price growth; core demand weakening under price pressure
EBITDA +2.4% YoY vs revenue +21.2% YoY; operating leverage reversed; costs outpacing gains
Ecosis targets backed off; ₹80–90 Cr EBITDA no longer disclosed; 7–8K MT vs 27K capacity utilization risk
PFI expansion deferred from FY27 to FY28; capex timelines slipped weeks; execution risk remains
Customer concentration in Ecosis (4 customers); loss of one could impact revenue 20%+
Risks, ranked by how much they should concern a holder
Margin compression in core business accelerates
HighVolume down 8.3% YoY; EBITDA +2.4% YoY vs revenue +21.2% signals cost inflation (raw materials, logistics) outpacing price realization. If crude oil spikes, demand may remain subdued.
Ecosis commercialization delayed; customer ramp stalls
HighOnly 7–8K MT firm commitments vs 27K TPD capacity. Trials started mid-Nov; first orders expected Dec-end. If customer approvals slip, the ₹80–90 Cr EBITDA target is unreachable.
Capex execution slips further; machinery delays persist
MediumBrownfield machinery arrived late; Ecosis trials started later than planned. 67% commissioned but weeks behind. ₹230 Cr ECB outstanding. Any further delay pushes earnings accretion into FY28/FY29.
Volume pressure continues if crude-price volatility persists
MediumBuyers delayed purchases during price spikes (volume down 8.3% YoY). If oil prices remain volatile, demand stays cautious even as Brownfield/Ecosis come online.
Customer concentration in Ecosis; customer loss risk
MediumDecathlon, A&E, H&M, IKEA are early movers. Loss of one customer could impact 20%+ of Ecosis revenue once the plant ramps.
How the street is positioned — and the disconnect
Filatex's stock has rallied 207% from its 52-week low (₹36.26) to ₹111.32 as of today. The trend is bullish: the stock trades above its 20-day, 50-day, and 200-day averages. Yet it is down 7% from its all-time high (₹119.74). The RSI at 66.4 is neutral — neither overbought nor oversold. Volume has been increasing, signaling institutional interest. The institution-buying signal is real. Foreign investors added 229 basis points of ownership in the quarter, rising from 4.03% (Q1) to 6.32% (Q2). Domestic institutions added 174 bps, rising from 2.85% to 4.59%. This is classic accumulation: the stock is below its ATH and institutions are buying into the dip. But there is a disconnect. The stock has rallied sharply and institutions are adding, yet the fundamental story is deteriorating. Volume is down 8.3%, margins are compressing (EBITDA +2.4% YoY vs revenue +21.2%), and guidance targets have been backed off. The long-term capex plan is credible (Brownfield +Ecosis +2 new plants, FTA tailwinds, domestic PTA supply), but the near-term earnings trajectory is weakening. The market appears to be pricing in a successful execution of that long-term plan — a 'show me' moment for Ecosis and Brownfield. If execution slips further, the stock's rally could reverse sharply from near-ATH.
The debate: what has to happen next
1 · Brownfield FDY lines commissioning (Nov 25, 2026)
The balance of the ₹235 Cr Dahej expansion should be live. Delivery on this target (currently 67% commissioned) is the credibility test for capex execution.
2 · Ecosis first commercial batch (expected Dec 2026)
Polymerization trials started mid-November. First commercial batch and customer order placements will determine whether Ecosis can scale from 7–8K MT commitments.
3 · Volume recovery as prices stabilize
The 8.3% YoY volume decline is the real weakness. If polyester prices stabilize and crude volatility eases, demand should return. Watch Q3/Q4 volume data closely.
4 · PFI expansion timeline confirmation (early 2027)
The ₹150–200 Cr revenue target is deferred to FY28. Confirmation of a concrete commissioning date in early 2027 will be critical to investor confidence.
5 · FY28 guidance: when will margins stabilize?
Management has backed off near-term targets. The key will be when FY28 guidance is provided. If it shows margin recovery via Brownfield ramp, Ecosis contribution, and domestic PTA supply, the case for a re-rating becomes compelling.
Filatex is a solid long-term story executing a credible capex plan, but near-term earnings are under pressure. Price-driven revenue growth masking volume decline and margin compression is a warning signal. The stock's rally to near-ATH on these deteriorating fundamentals argues for patience. Hold for the long-term plan, but wait for concrete proof of Ecosis and Brownfield execution before adding. The number to track from here is organic volume growth; if volumes remain down, core business deterioration will eventually swamp the upside from new projects. That is the debate that matters most.
Informational and educational content only. Not investment advice.